MapLight Therapeutics releases Phase 2 IRIS trial topline data for ML-004 in autism
MapLight Therapeutics announced topline data from its Phase 2 IRIS trial evaluating ML-004 for autism spectrum disorder treatment. The clinical trial results represent a key milestone in the company's development pipeline for this therapeutic candidate.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day